Figure 3 | Scientific Reports

Figure 3

From: Matrix-bound nanovesicles prevent ischemia-induced retinal ganglion cell axon degeneration and death and preserve visual function

Figure 3

MBV decrease IOP-induced RGC death. (a) Representative images show RGC cell bodies co-labeled with RBPMS (Green) and Brn3A (Red) in the uninjured central and peripheral retina (Control), in the IOP-injured retina (IOP), and in IOP-injured retinas treated with either PBS (IOP + PBS) or MBV (IOP + MBV). (b) To determine in vivo toxicity, MBV were injected intravitreally at 5, 10, or 20 µg/ml, on days 0, 2, and 7 into healthy, uninjured rat eyes and analyzed at 14 days. Compared to uninjected controls, RGC viability was unchanged by either PBS or MBV at 5-µg/ml. However, viability was  reduced in the central but not in the peripheral retina by 10- and 20-µg/ml MBV injections at 14 days. (c,d) In IOP-injured eyes, MBV decreased IOP-induced RGC loss in both the (c) Central and in the (d) Peripheral retina compared to IOP-injured and IOP-injured with PBS injections. Data represent n = 5 animals per group and 12 images per retina, totaling 60 images per group. Error bars indicate the SEM. One-way ANOVA with Post-hoc Tukey’s test determined significance between groups, *p < 0.05, and compared to uninjured control, #p < 0.05.

Back to article page